233 related articles for article (PubMed ID: 28453725)
1. Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy.
Nonhoff J; Ricke-Hoch M; Mueller M; Stapel B; Pfeffer T; Kasten M; Scherr M; von Kaisenberg C; Bauersachs J; Haghikia A; Hilfiker-Kleiner D
Cardiovasc Res; 2017 May; 113(6):598-608. PubMed ID: 28453725
[TBL] [Abstract][Full Text] [Related]
2. In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles.
Ricke-Hoch M; Hoes MF; Pfeffer TJ; Schlothauer S; Nonhoff J; Haidari S; Bomer N; Scherr M; Stapel B; Stelling E; Kiyan Y; Falk C; Haghikia A; Binah O; Arany Z; Thum T; Bauersachs J; van der Meer P; Hilfiker-Kleiner D
Cardiovasc Res; 2020 Sep; 116(11):1875-1886. PubMed ID: 31711127
[TBL] [Abstract][Full Text] [Related]
3. Cabergoline treatment promotes myocardial recovery in peripartum cardiomyopathy.
Pfeffer TJ; Mueller JH; Haebel L; Erschow S; Yalman KC; Talbot SR; Koenig T; Berliner D; Zwadlo C; Scherr M; Hilfiker-Kleiner D; Bauersachs J; Ricke-Hoch M
ESC Heart Fail; 2023 Feb; 10(1):465-477. PubMed ID: 36300679
[TBL] [Abstract][Full Text] [Related]
4. Opposing roles of Akt and STAT3 in the protection of the maternal heart from peripartum stress.
Ricke-Hoch M; Bultmann I; Stapel B; Condorelli G; Rinas U; Sliwa K; Scherr M; Hilfiker-Kleiner D
Cardiovasc Res; 2014 Mar; 101(4):587-96. PubMed ID: 24448315
[TBL] [Abstract][Full Text] [Related]
5. Low STAT3 expression sensitizes to toxic effects of β-adrenergic receptor stimulation in peripartum cardiomyopathy.
Stapel B; Kohlhaas M; Ricke-Hoch M; Haghikia A; Erschow S; Knuuti J; Silvola JM; Roivainen A; Saraste A; Nickel AG; Saar JA; Sieve I; Pietzsch S; Müller M; Bogeski I; Kappl R; Jauhiainen M; Thackeray JT; Scherr M; Bengel FM; Hagl C; Tudorache I; Bauersachs J; Maack C; Hilfiker-Kleiner D
Eur Heart J; 2017 Feb; 38(5):349-361. PubMed ID: 28201733
[TBL] [Abstract][Full Text] [Related]
6. Relaxin-2 and Soluble Flt1 Levels in Peripartum Cardiomyopathy: Results of the Multicenter IPAC Study.
Damp J; Givertz MM; Semigran M; Alharethi R; Ewald G; Felker GM; Bozkurt B; Boehmer J; Haythe J; Skopicki H; Hanley-Yanez K; Pisarcik J; Halder I; Gorcsan J; Rana S; Arany Z; Fett JD; McNamara DM;
JACC Heart Fail; 2016 May; 4(5):380-8. PubMed ID: 26970832
[TBL] [Abstract][Full Text] [Related]
7. Perhexiline treatment improves toxic effects of β-adrenergic receptor stimulation in experimental peripartum cardiomyopathy.
Pfeffer TJ; List M; Müller JH; Scherr M; Bauersachs J; Hilfiker-Kleiner D; Ricke-Hoch M
ESC Heart Fail; 2021 Aug; 8(4):3375-3381. PubMed ID: 34002539
[TBL] [Abstract][Full Text] [Related]
8. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy.
Hilfiker-Kleiner D; Kaminski K; Podewski E; Bonda T; Schaefer A; Sliwa K; Forster O; Quint A; Landmesser U; Doerries C; Luchtefeld M; Poli V; Schneider MD; Balligand JL; Desjardins F; Ansari A; Struman I; Nguyen NQ; Zschemisch NH; Klein G; Heusch G; Schulz R; Hilfiker A; Drexler H
Cell; 2007 Feb; 128(3):589-600. PubMed ID: 17289576
[TBL] [Abstract][Full Text] [Related]
9. ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy.
Feyen E; Ricke-Hoch M; Van Fraeyenhove J; Vermeulen Z; Scherr M; Dugaucquier L; Viereck J; Bruyns T; Thum T; Segers VFM; Hilfiker-Kleiner D; De Keulenaer GW
Circ Heart Fail; 2021 Jul; 14(7):e006898. PubMed ID: 34247489
[TBL] [Abstract][Full Text] [Related]
10. Reperfusion therapy with recombinant human relaxin-2 (Serelaxin) attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism.
Valle Raleigh J; Mauro AG; Devarakonda T; Marchetti C; He J; Kim E; Filippone S; Das A; Toldo S; Abbate A; Salloum FN
Cardiovasc Res; 2017 May; 113(6):609-619. PubMed ID: 28073832
[TBL] [Abstract][Full Text] [Related]
11. Proteomic Profiling in Patients With Peripartum Cardiomyopathy: A Biomarker Study of the ESC EORP PPCM Registry.
Kodogo V; Viljoen C; Hoevelmann J; Chakafana G; Tromp J; Farhan HA; Goland S; van der Meer P; Karaye K; Kryczka K; Hilfiker-Kleiner D; Jackson A; Mebazaa A; Böhm M; Pieske B; Bauersachs J; Bell L; Sliwa K;
JACC Heart Fail; 2023 Dec; 11(12):1708-1725. PubMed ID: 37804308
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-146a is a therapeutic target and biomarker for peripartum cardiomyopathy.
Halkein J; Tabruyn SP; Ricke-Hoch M; Haghikia A; Nguyen NQ; Scherr M; Castermans K; Malvaux L; Lambert V; Thiry M; Sliwa K; Noel A; Martial JA; Hilfiker-Kleiner D; Struman I
J Clin Invest; 2013 May; 123(5):2143-54. PubMed ID: 23619365
[TBL] [Abstract][Full Text] [Related]
13. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy.
Patten IS; Rana S; Shahul S; Rowe GC; Jang C; Liu L; Hacker MR; Rhee JS; Mitchell J; Mahmood F; Hess P; Farrell C; Koulisis N; Khankin EV; Burke SD; Tudorache I; Bauersachs J; del Monte F; Hilfiker-Kleiner D; Karumanchi SA; Arany Z
Nature; 2012 May; 485(7398):333-8. PubMed ID: 22596155
[TBL] [Abstract][Full Text] [Related]
14. [Comparison and analysis of different diagnostic criteria for peripartum cardiomyopathy].
Wang Y; Gao Z; Liu GL; Wei J; Zhang XH; Wang JL
Zhonghua Fu Chan Ke Za Zhi; 2011 Jul; 46(7):487-91. PubMed ID: 22041438
[TBL] [Abstract][Full Text] [Related]
15. EURObservational Research Programme: a worldwide registry on peripartum cardiomyopathy (PPCM) in conjunction with the Heart Failure Association of the European Society of Cardiology Working Group on PPCM.
Sliwa K; Hilfiker-Kleiner D; Mebazaa A; Petrie MC; Maggioni AP; Regitz-Zagrosek V; Schaufelberger M; Tavazzi L; van Veldhuisen DJ; Roos-Hesslink JW; Shah AJ; Seferovic PM; Elkayam U; van Spaendonck-Zwarts K; Bachelier-Walenta K; Mouquet F; Kraigher-Krainer E; Hall R; Ponikowski P; McMurray JJ; Pieske B
Eur J Heart Fail; 2014 May; 16(5):583-91. PubMed ID: 24591060
[TBL] [Abstract][Full Text] [Related]
16. Peripartum cardiomyopathy: basic mechanisms and hope for new therapies.
Ricke-Hoch M; Pfeffer TJ; Hilfiker-Kleiner D
Cardiovasc Res; 2020 Mar; 116(3):520-531. PubMed ID: 31605117
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study.
Sliwa K; Blauwet L; Tibazarwa K; Libhaber E; Smedema JP; Becker A; McMurray J; Yamac H; Labidi S; Struman I; Hilfiker-Kleiner D
Circulation; 2010 Apr; 121(13):1465-73. PubMed ID: 20308616
[TBL] [Abstract][Full Text] [Related]
18. Phenotyping and outcome on contemporary management in a German cohort of patients with peripartum cardiomyopathy.
Haghikia A; Podewski E; Libhaber E; Labidi S; Fischer D; Roentgen P; Tsikas D; Jordan J; Lichtinghagen R; von Kaisenberg CS; Struman I; Bovy N; Sliwa K; Bauersachs J; Hilfiker-Kleiner D
Basic Res Cardiol; 2013 Jul; 108(4):366. PubMed ID: 23812247
[TBL] [Abstract][Full Text] [Related]
19. Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy.
Bauersachs J; König T; van der Meer P; Petrie MC; Hilfiker-Kleiner D; Mbakwem A; Hamdan R; Jackson AM; Forsyth P; de Boer RA; Mueller C; Lyon AR; Lund LH; Piepoli MF; Heymans S; Chioncel O; Anker SD; Ponikowski P; Seferovic PM; Johnson MR; Mebazaa A; Sliwa K
Eur J Heart Fail; 2019 Jul; 21(7):827-843. PubMed ID: 31243866
[TBL] [Abstract][Full Text] [Related]
20. Systematic review and meta-analysis of prolactin and iron deficiency in peripartum cardiomyopathy.
Cherubin S; Peoples T; Gillard J; Lakhal-Littleton S; Kurinczuk JJ; Nair M
Open Heart; 2020 Oct; 7(2):. PubMed ID: 33060142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
